Patent Litigation, 2021


Book Description




U.S. Biotechnology Patent Law


Book Description




Patent Litigation and Strategy


Book Description

This book sets out governing statutes and rules at the beginning of each chapter and includes sample litigation documents where possible. The casebook begins with discussions of who to sue, where to sue, pleading requirements, discovery, and trial strategy. It then moves into substantive legal issues. The Third Edition includes new material on pharmaceutical litigation under the Hatch-Waxman Act and the most developments in the law of invalidity and infringement. The book next addresses issues surrounding remedies, including injunctive relief (with a discussion of the Supreme Court's eBay decision), contempt proceedings, and damages. Also included are post-trial matters including jury instructions, special verdict forms, the preclusive effect of final judgments, judgment as a matter of law, and new trial motions. Finally, the book covers the appeal process and reexamination and reissue proceedings.




Patent Disputes


Book Description

Patent Disputes: Litigation Forms and Analysis, Second Edition contains over 60 full-length agreements - with accompanying checklists and commentary - covering virtually every area of patent litigation in federal courts and before other administrative bodies, such as interpartes proceedings in the PTO. The book is organized sequentially, following the course of the litigation process - from complaint to appeals. Forms include: Sample complaints for federal court and administrative proceedings Sample answers, counterclaims and third party complaints Sample motions ranging from Motion to Dismiss to Motions for Sanctions/Attorney's Fees Discovery forms, such as interrogatories and protective orders Forms for Markman Hearings Trial forms such as jury instructions Forms for appeal such as Notice of Appeal, and Petition for Cert With your purchase of Patent Disputes: Litigation Forms and Analysis, Second Edition, you'll also receive the bonus companion CD-ROM containing fully customizable versions of all of the forms and documents in the book.




Patent Law Institute 2021


Book Description




Patents as an Incentive for Innovation


Book Description

Patents as an Incentive for Innovation Edited by Rafal Sikorski & Zaneta Zemla-Pacud Patents are a reward for human inventiveness. A well-functioning patent system must provide incentives for innovation, safeguard dynamic competition and protect the public interest – a balancing act fraught with difficulty in the ‘connected’ global world. This ground-breaking book is the first to deeply analyse how patent law today performs its function of stimulating innovation in the crucial sectors of healthcare, agriculture, artificial intelligence and communications technology. Patent specialists, practitioners and scholars from various jurisdictions thoroughly describe how patent rights can be deployed to incentivize investments in researching and developing socially critical innovations without sacrificing the public’s interest in sharing the benefits that are produced. Among the emerging issues of patent rights investigated are the following: protectability and morality of according private rights over material derived from the human body; licensing on fair, reasonable and non-discriminatory (FRAND) terms; the supplementary protection certificate (SPC) manufacturing waiver; patent eligibility of artificial intelligence-related inventions; excessive enforcement of patents by patent assertion entities; enforcement of second medical use innovations; the so-called farmer’s privilege, the farm-save seed exemption, and breeders’ rights; international trade regulations and their influence on patent systems; human enhancement technologies and the consequences of patenting them; specifics of patent protection for biologic medicines; challenges posed by artificial intelligence for the disclosure requirement in patent law; and standard essential patent licensing, particularly in the context of the 5G standard. Perspectives taken into consideration by the authors include protectability criteria, length and scope of the granted protection, mechanisms for dealing with the friction between generalized application and specialized concerns, and rights enforcement. These aspects are analysed on the domestic, international and global levels. The COVID-19 pandemic has highlighted the urgent need to strike the right balance between innovation and access in healthcare and other technologies, a need rooted in patent law. Because the problems discussed – and solutions offered – in this collection of expert essays are of tremendous practical and cultural significance, the book will be of immeasurable value to practitioners, policymakers and researchers in patent law and other fields of intellectual property law.




Modern Patent Litigation


Book Description

To access the book's 2010 Statutory Supplement, click here. To access the book's 2011 case update, click here. Modern Patent Litigation was the first casebook to deal exclusively with the substantive issues that arise in patent litigation. Now, the original edition has been extensively updated to account for the very important case law developments over the last six years in patent litigation. Included are new cases on patent claim interpretation, the patent-antitrust interface, summary judgment standards, attorney-client privilege, and measures of damages. New notes have also been added to reflect newly emerging issues in the field, such as the revised thinking on convoyed sales as a damages element and the meaning of "acting in concert" with regard to injunctions. Designed for use in an advanced course on patent law, this book is written for students who have already completed a course in basic patent law. Janicke concentrates on patent claims as determinants of coverage and lays out the subject in terms of the power of patent litigation. A chapter on remedies of the accused infringer deals primarily with declaratory relief, attorneys' fees, and indemnity. Other chapters include jurisdictional and venue issues in patent cases, the various kinds of estoppels that may be operative, details of affirmative defenses, and the impact of a particular judgment on later proceedings involving the same patent.




Biotechnology Patent Law Top Ten of 2021 Experimentation, Blaze Marks, and Unspecified Ranges


Book Description

Biotechnology has never demonstrated its benefits to society more than in 2021. The SARS-CoV-2 virus that caused the CoVID-19 pandemic met a formidable opponent in mRNA vaccines developed and supplied by Moderna and Pfizer/BioNTech. These vaccines are claimed in myriad - not Myriad - patents and patent applications, many of which are destined to be litigated over the coming years, not least inspired by the many billions of dollars that have been, and will continue to be, earned by their owners. While the world waits for this storm of patent litigation, federal courts continue to be busy with ownership, licensing, validity, and infringement disputes arising from other biotechnologies, including, perhaps, up-and-coming CAR-T therapies. For the fourth year in a row (of what has become a tradition), we discuss, in this article, the ten most consequential, important, and interesting court decisions involving biotechnology patents. Our top ten decisions may not be the same as top tens compiled by others. However, to quote an expression commonly heard in courts hearing patent cases, à chacun son goût. Patent decisions delivered during 2021 tackled a diverse group of doctrinal issues. As discussed in the article, these ranged from how much experimentation is to be considered undue à la In re Wands, to what level of detail of disclosure is sufficient to satisfy the ever- written description requirement, to which types of behavior may rise to the level of inducement to infringe, not to mention assignor estoppel. Patent litigations filed in federal district court rose to 3,798, a number not seen since 2016. In contrast, the 1,333 patent actions filed with the Patent Trial and Appeal Board (“PTAB“) represented a substantial decline from 2020. In short, despite the challenges of the CoVID-19 pandemic, patent litigation in 2021 evinced considerable vim and vigor. Described and analyzed in this article are the vimmiest and most vigorous of 2021 patent decisions.




Patent Litigation


Book Description

Patent Litigation shows you how to spot and shore up weaknesses in your case; make effective pretrial, trial, and post-trial motions; enhance your direct-examination and cross-examination skills; accurately measure and prove the amount of damages; and achieve favorable settlements when litigation is not the way to go.